• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • TheStreet Smarts
  1. Home
  2. / Investing
  3. / Stocks

A Recession Appears Inevitable, but There Are Still Places to Invest

A few homebuilders and healthcare stocks seem likely to hold up better than most of the market in a recession.
By BRET JENSEN
Jul 27, 2022 | 10:30 AM EDT
Stocks quotes in this article: WEBR, WMT, TOL, FLGT

In Monday's column I highlighted the extreme challenges the retail sector now faces. We have received more confirmation about the negative impact of the current economic environment on profit margins in the retail space since that piece ran.

The shares of outdoor grill maker Weber Inc. (WEBR) got taken to the woodshed in Monday's trading after the company withdrew its guidance for fiscal 2022 sales and jettisoned its CEO. If there is a canary in the coal mine as it relates to discretionary spending, Weber might be it. Weber also continues to be burdened with the supply chain issues that have plagued the retail industry. Then after the closing bell on Monday, retail giant Walmart (WMT) slashed its profit guidance, both for the quarter and the fiscal year. The stock sold off nearly 8% in trading Tuesday.

There also were more signs that a recession is growing more imminent as on Tuesday the June home sales report showed sales fell more than expected, the reading of July Consumer Confidence missed the consensus and the two-year and 10-year Treasury yields inverted more than at any time since 2006. The fact that the Treasury secretary is out making the rounds saying she doesn't see a recession on the horizon and the administration is trying to redefine what a recession is gives me even greater confidence that we either are in an economic contraction already or soon will be. The expected 75-basis-point rate hike by the Federal Reserve here on Wednesday sure isn't going to do anything to improve growth prospects.

Over the next few weeks investors will be treated to myriad downward price target revisions across a broad number of industries as analysts factor recent earnings reports, company guidance and a decaying economy into their outlooks. I could see these actions triggering the next leg down in the market. That is why I remain cautious and am keeping a significantly higher allocation of cash than usual in my portfolio. Whatever dry powder I am deploying is going toward names that still would be cheap if earnings expectations dropped by a quarter or more, such as some home builders, Toll Brothers (TOL) among them.

I am also increasing my allocation to the healthcare sector, the profits of which should hold up much better than the rest of the market within a recession. One new healthcare concern in my portfolio is Fulgent Genetics (FLGT) , which I open an initial position in via covered calls this week as options against the equity are both lucrative and cheap.

Fulgent was a huge beneficiary of the pandemic as its revenue boomed thanks to the Covid-19 tests this diagnostic firm supplies. However, the stock is down nearly two-thirds from its all-time highs made in January 2021 during the height of coronavirus worries. It is true that Covid testing sales will continue to ebb as we move past this historic outbreak. However, Fulgent is well-positioned to survive that drop as management has built a huge cash hoard that it has deployed in scarfing up a couple bolt-on acquisitions over the past year. I expect Fulgent to continue to be active in on the acquisition front as it builds its comprehensive diagnostic platform.

At less than 10x this year's profits -- half of that if equating for the net cash on the balance sheet -- the shares seem more than cheap even as I am not sanguine on the overall market.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Jensen was long FLGT and TOL.

TAGS: Economy | Federal Reserve | Interest Rates | Investing | Stocks | Housing Market | Health Care Equipment & Services | Healthcare | Real Money

More from Stocks

This Is No Time to Put Money to Work

James "Rev Shark" DePorre
Oct 2, 2023 4:04 PM EDT

The government shutdown deal did little to move stocks on Monday after the open.

Microsoft: Will Strength or Weakness Win Out?

Bruce Kamich
Oct 2, 2023 2:26 PM EDT

Let's check the charts and indicators.

Trading Coinbase Is More Than Just a Flip of the Coin

Bruce Kamich
Oct 2, 2023 1:30 PM EDT

The stock rallied early Monday, but those gains are fading.

Oil's on the Front Burner, and It's Getting Overcooked

Peter Tchir
Oct 2, 2023 12:30 PM EDT

Let me show you with one simple chart why the moves in this energy commodity are overhyped.

The Magnificent Seven Are Regaining Momentum

James "Rev Shark" DePorre
Oct 2, 2023 11:50 AM EDT

I have taken a position in one of these 'magnificent' names, and have my eyes on an under-the-radar asset manager.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 12:13 PM EDT BRUCE KAMICH

    8 Trading Rules from T. T. Hoyne

    You just read the header for this missive and prob...
  • 08:42 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    How Elite Traders Make Big Profits
  • 02:58 PM EDT BRUCE KAMICH

    Classic Trading Rules From Bernard Baruch

    Bernard Baruch listed the rules (below) in his aut...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2023 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login